NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 2017
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
4
Data completeness
4/8 — Partial
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYZULTA (latanoprostene bunod) is a fixed-combination ophthalmic solution approved in 2017 for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It combines a prostaglandin analog with a nitric oxide donor, working through dual mechanisms to reduce IOP. The drug is administered as once-daily eye drops.
$0.117BPart D
LOE ApproachingStable
2.3 years to LOEProduct approaching loss of exclusivity in 2029 with stable Medicare spending; brand teams should prepare transition strategies and line extensions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension
Started May 2022
0Ocular Hypertension
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
Started Dec 2018
70 enrolled
OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
Started Jul 2013
130 enrolled
GlaucomaOcular Hypertension
Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
Started Jul 2013
24 enrolled
Intraocular Pressure
Worked on VYZULTA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.